Canine leishmaniasis is endemic in Spain, where approximately 5% of the dog population are infected. Diagnosis of the disease relies on direct examination and culture of lymph nodes or bone marrow aspirates and serologic techniques. Interpretation of results obtained by serologic techniques (ELISA, dot-ELISA, immunofluorescence assay [IFA]) when dogs from endemic areas are examined is often difficult. Although these techniques can detect active leishmaniasis when a high level of specific antibodies is present, they do not distinguish between the various phases of the disease when levels of antibodies are at or near the cut-off level. Different seroepidemiologic studies performed in the Mediterranean area, indicate that the proportion of sera with low antibody titers is directly related to the level of endemicity. The study of the natural evolution of leishmaniasis in the Priorat focus of northeastern Spain by a dot-ELISA technique showed that 40% of the dogs examined had low antibody titers. This low level of antibodies may be a consequence of the latent period of the disease, which can last from a few months to several years, abortive or regressive forms of the disease, a low humoral immunoresponse in the animal, or different host-parasite contacts without the establishment of the parasite. Distinguishing between these situations is of great importance clinically and epidemiologically.

Recent studies reported different results concerning the pattern obtained in Western blot analysis of the specific humoral immunoresponse to Leishmania antigens during the active course of the disease and during therapy in human leishmaniasis. Limited studies have been performed on dogs, and little is known about the natural evolution of this immunoresponse during active or latent asymptomatic canine infection, or during regression of the disease.

The aim of this study was to define the polypeptide fractions of the Leishmania antigen that might be used in the diagnosis of the disease, and to determine whether the pattern obtained in Western blots could be used as a marker for the evolution of disease.

MATERIALS AND METHODS

Sera. Sera were obtained from 237 dogs in Catalonia (northeastern Spain), an area endemic for leishmaniasis, 72 of which had leishmaniasis as confirmed by direct examination and/or culture. Forty-one were treated at the Veterinary Hospital of the Facultat de Veterinaria de Bellaterra in Barcelona, and 31 were from a focus of leishmaniasis in Priorat.

Sera from 165 animals from the natural focus in Priorat (south of Catalonia) were periodically studied for 2–8 years between 1987 and 1995, giving a total of 565 determinations, with a mean of 3.4 determinations per dog (range = 2–8). Clinical examination and blood collection were carried out during the annual antirabies vaccination campaign. Complete records of breed, sex, age, and size, were obtained for epidemiologic purposes and clinical signs for leishmaniasis were evaluated. Dogs were classified as asymptomatic when there was no indication of Leishmania infection (moderately enlarged lymph nodes found in a few cases were disregarded); oligosymptomatic when moderate symptoms, including two signs of infection (enlarged lymph nodes and onychogryposis or furfuraceous dermatitis/depilation) were observed; and symptomatic when evident symptoms including three or more signs of disease were observed.

Animals were examined at annual intervals. Many of the animals died during the study without the cause of death being established, and a large number of animals were also lost during the study for a variety of reasons, such as changes in residence and lack of permission of the owner to continue the study. Parasitologic examination (direct examination and culture) could be performed only in some cases due to difficulties in collecting repeated ganglionic aspirates.
under field conditions and from apparently healthy dogs. A control group of 93 dogs from nonendemic areas (Switzerland, Sweden, and the Canary Islands) was also studied.

Blood samples were allowed to clot, and the serum was separated by centrifugation and stored at −40°C until use.

**Dot-ELISA.** The technique was performed as previously described. Briefly, the antigen used was whole promastigotes of *L. infantum* fixed in 1.5% formaldehyde. Dots of 1 μl containing 10^4 cells were adsorbed onto a nitrocellulose membrane in a bio-dot apparatus (Bio-Dot®; Bio-Rad, Hercules, CA). Fifty microliters of serially diluted serum samples (from 1:100) in 20 mM Tris, 0.13 mM NaCl, pH 7.6, containing 0.05% Tween 20 (TST) and 1% dry skim milk was added to each well and incubated at 37°C for 30 min. After the dots were washed with TST, 50 μl of Protein A labeled with horseradish peroxidase (Sigma, St. Louis, MO) diluted 1:1,000 in TST was added and incubated at 37°C for 30 min. After washing with TST, the entire membrane was exposed to the chromogen reagent (4-chloro-1-naphthol [Sigma]) and H_2O_2. Color development was visually determined and the cut-off value was established at a 1:800 dilution of serum.

**Immunoblot analysis.** Antigen for immunoblot was obtained from promastigotes from culture in Schneider's medium (Sigma) containing 20% fetal calf serum at the exponential growth phase. Cells were washed three times in phosphate-buffered saline, pH 7.4, counted, and adjusted to a concentration of 3 × 10^6 promastigotes/ml in sample buffer (0.5 M Tris-HCl, pH 6.8, 0.01 M EDTA, 5% sodium dodecyl sulfate [SDS], 5% 2-mercaptoethanol, 0.0125% bromophenol blue), and boiled for 5 min. Antigen was stored at −40°C until use.

Antigen electrophoresis on 0.1% SDS-15% polyacrylamide gels together with molecular mass proteins standards (Standard Low Range; Bio-Rad) was performed on a Mini-Gel AE 6400 Dual Mini Slab Kit (Atto, Bunkyo-ku, Japan). Gels were run at 80 V for 2 hr at room temperature. Polypeptides were transblotted onto nitrocellulose sheets (0.45-μm pore size, HAWP 304 FO; Millipore, Bedford, MA) and the sheets were blocked with 20 mM Tris, 0.13 mM NaCl, pH 7.6 (TS), 5% skim milk overnight at 4°C until use.

**Results**

Seventy of 72 dogs with leishmaniasis had antibodies that revealed 3–33 polypeptide fractions of the *Leishmania* antigen with a molecular mass range between 12 and 85 kD. The highest sensitivity was found for bands of 70, 65, 46, 30, 28, 14, and 12 kD (Table 1). The specificity of the technique was calculated with the sera of 93 dogs from nonendemic areas. Sera of four dogs from Sweden reacted with some fractions of the *Leishmania* antigen (75–70, 75–60, 65–60, 58, and 34 kD, respectively). The coefficient of contingency for each band and the presence of parasite (χ^2), and intensity of this relation (C-Pearson’s coefficient of contingency) is presented in Table 1.

The specificity of the technique was calculated with the sera of 93 dogs from nonendemic areas. Sera of four dogs from Sweden reacted with some fractions of the *Leishmania* antigen (75–70, 75–60, 65–60, 58, and 34 kD, respectively). The coefficient of contingency for each band and the presence of parasite was calculated (Table 1), and the strongest relationship was found for bands of 46, 30, 28, 14, and 12 kD. Based on these results, we considered the Western blot to be positive when any one of the latter bands was present and the sensitivity of the technique was calculated to be 95.8%.

None of the animals negative by Western blot was positive by dot-ELISA (> 1:400) and although a direct relationship between the results obtained in the dot-ELISA and the Western blot could not be established, in general, the number of bands in the immunoblot increased with the titer obtained by the dot-ELISA (Figure 1). The sensitivity obtained with this technique for the same animals was 91.6%.

**Epidemiologic study.** One hundred sixty-five dogs from the Priorat focus of leishmaniasis were studied serologically (Western blot and dot-ELISA) for 2–8 years. With regards to the serologic evolution of the animals, we observed the following results. 1) Seventy-four of 165 dogs (group A)
were negative throughout the study by Western blot (sera did not reveal any antigen band of *Leishmania*) and negative by dot-ELISA or less than the cut-off value. This group can be considered as the cohort of negative animals and none of them had symptoms of *Leishmania* infection. 2) Thirteen of 165 dogs (group B) remained Western blot positive throughout the study. The symptoms of these dogs changed during the study; eight were asymptomatic at the beginning of the study but only three of them remained healthy at the last examination (Figure 2). 3) Twenty-nine of 165 dogs (group C) seroconverted. In these cases, the number of antigenic fractions recognized increased gradually after the first appearance of bands of 12 and 14 kD (e.g., dogs 58, 140, and 145, Figure 3). Nineteen of 29 were asymptomatic at all times, whereas 10 of 29 were oligosymptomatic at the last examination. 4) Seven of 165 dogs (group D) showed a clear reduction in the number of bands, together with a decrease in the dot-ELISA titer. These animals were always asymptomatic or oligosymptomatic; this was accompanied by a reduction and/or disappearance of bands of low molecular weights, (e.g., dogs 113 and 140, Figure 3). In two cases there was an increase and a later reduction in the number of bands in Western blots and in the titer of the dot-ELISA. We believe that this corresponds to the self-healing population. 5) Serum observed from 38 of 165 dogs (group E) showed at certain times proteins corresponding to bands not included among those considered diagnostic (46, 30, 28, 14, and 12 kD). All of these dogs were negative by dot-ELISA or had an antibody level less than the cut-off value (< 1:800), and none became positive (either by dot-ELISA or Western blot) during the period of the study (Figure 4). Twelve of the 38 dogs showed a single band of 70 kD. This single band was also seen in the serum of one dog in group D (number 113, Figure 3), which later became seronegative (by dot-ELISA and Western blot) for three consecutive years. 6) Six of 165 dogs (group F) were observed that could not be included in any of the above groups.

The relationship between results in the dot-ELISA and Western blots for each sera and the clinical status of the animals at the time of sampling is shown in Table 2. Most sera with a negative dot-ELISA result (375) also had a negative Western blot result (365), and most sera with a positive

---

**Figure 1.** Comparison of the results obtained by dot-ELISA and Western blot (WB) in 72 dogs with leishmaniasis confirmed by direct examination and/or culture.

**Figure 2.** Western blot analysis of sera from three positive dogs (dot-ELISA, Western blot, and culture). Lanes a and b, dog no. 36; a, 1991, dot-ELISA 1:1,600, asymptomatic; b, 1992, dot-ELISA 1:1,600, asymptomatic. Lanes c and d, dog no. 31; c, 1991, dot-ELISA 1:6,400, asymptomatic; d, 1992, dot-ELISA 1:6,400, symptomatic. Lanes e and f, dog no. 18; e, 1991, dot-ELISA 1:3,200, asymptomatic; f, 1992, dot-ELISA 1:3,200, asymptomatic. All dogs died in 1993. Values on the right are in kilodaltons.
FIGURE 3. Western blot analysis of serum of four dogs in which the titer in the dot-ELISA and the Western blot pattern changed over time. Lanes a–c, dog no. 58; a, 1990, dot-ELISA 1:100; b, 1991, dot-ELISA 1:1,600; c, 1992, dot-ELISA 1:6,400; the dog remained asymptomatic. Lanes d–h, dog no. 145; d, 1988, dot-ELISA 1:200; e, 1989, dot-ELISA 1:400; f, 1991, dot-ELISA 1:800; g, 1992, dot-ELISA 1:800; h, 1993, dot-ELISA 1:800; the dog remained asymptomatic with the exception of 1992 when slight adenopatia and scattered depilations on the skin were observed. Lanes i–n, dog no. 140; i, 1989, dot-ELISA negative; j, 1990, dot-ELISA 1:100; k, 1991, dot-ELISA 1:200; l, 1992, dot-ELISA 1:800; m, 1993, dot-ELISA 1:100; n, 1994, dot-ELISA 1:100; cultures of lymph node aspirates and bone marrow were positive in 1992 and the dog remained asymptomatic in the control period. Lanes o–s, dog no. 113; o, 1991, dot-ELISA 1:400; p, 1992, dot-ELISA 1:100; q, 1993, dot-ELISA negative; r, 1994, dot-ELISA negative; s, 1995, dot-ELISA negative; the dog remained asymptomatic with the exception of the control in 1995, which had depilations on the ears. Values on the right are in kilodaltons.

dot-ELISA result (61) also had a positive Western blot result (57). Only four sera positive by dot-ELISA had a negative Western blot result. In all cases these dot-ELISA titers were near the cut-off value (1:800) and Western blots revealed bands other than those considered diagnostic. One of these dogs became positive by Western blot and the dot-ELISA titer increased to 1:3,200 in a second control; another dog died the following year of undetermined causes and two retained dot-ELISA titers less than the cut-off value and Western blots with nonspecific bands for next two and three years, respectively. Ten sera from eight asymptomatic dogs with negative dot-ELISA results had positive Western blots; five dogs were from group C and the bands were 14 or 12–14 kD, and seroconversion by dot-ELISA was observed after a variable period of time. For the remaining three dogs, no additional data was available to evaluate the serology.

One-hundred twenty-nine sera with a dot-ELISA titer less than the cut-off value corresponded to dogs included in all the categories established above. In 58 sera, the Western blot was negative and corresponded to dogs in group A. Another 37 sera were positive by Western blot and recognized a variable pattern of antigenic fractions; 14 of them showed reac-
tivity only to the 14 or 12–14 kD bands in dogs in group C. Low titers in the dot-ELISA and positivity by Western blot were also observed in sera obtained from dogs in group D. The remaining 34 sera with low dot-ELISA titers recognized bands not considered diagnostic in dogs in group E, and exceptionally, in group D.

Dogs with symptoms of Leishmania infections were always positive by Western blot and the pattern of antigenic fractions recognized was not different from that recognized by sera obtained during the asymptomatic phases of the disease when antibody levels were similar (Figure 2).

**DISCUSSION**

Immunoblot analysis has been recently found to be suitable for the diagnosis of visceral leishmaniasis in humans and in dogs. However, some investigators disagree as to the most specific and sensitive antigen bands recognized by sera of patients and animals with leishmaniasis. Differences in the antigens used, promastigotes from the exponential or stationary growth phase, different degrees of antigen reduction as a consequence of different concentrations of SDS and 2-mercaptoethanol in the sample buffer, and separation of the soluble fractions of the antigen and the pellet are some of the factors that could influence the results. Moreover, the size of the slab gels and the concentration of polyacrylamide used, as well as different molecular weight markers, may introduce slight variations in the separation of the fractions and in the relative molecular weights calculated.

The results obtained here are consistent with those obtained by Mary and others in patients with visceral leishmaniasis in which antigens of 14, 16, 28, 30, 46, and 68 kD were recognized by 92%, 95%, 63%, 80%, 69%, and 89% of the patients’ sera, and those of Mancianti and others in dogs, who found that all positive sera, even when the IFA titer was relatively low, recognized antigens of 30 and 73 kD. Other antigens frequently recognized were those with molecular weights of 16, 18, 26, 33, 50, and 117 kD. There may be identity between the 12-, 14-, 28-, 30-, 46-, and 70-kD antigens in the present study and the 14-, 16-, 28-, 30-, 46-, and 68-kD antigens reported by Mary and others and the 16-, 18-, 30-, 33-, 50-, and 73-kD antigens of Mancianti and others. In a recent study, proteins of 14 and 16 kD have been identified as nuclear proteins and designated p14 and p18.

The calculation of the sensitivity of the test in this study was performed on dogs with positive parasitologic examination results and with symptoms compatible with leishmaniasis. This combination of clinical signs and positive parasitologic examination results usually arises in advanced active diseases. This is why in most of these dogs, the dot-ELISA results were positive and the Western blots revealed a large number of bands (Figure 1). The epidemiologic study was performed on the canine population of the Priorat area that participated in an antirabies vaccination campaign and were not necessarily ill. In this case, many dogs were in the early subclinical phases of the disease. In rural areas of Catalonia such as the area studied, few dogs are specifically treated for leishmaniasis and many are killed when they are in the advanced phases of the disease. The study of serum in early phases, using techniques that do not distinguish between antigenic fractions (IFA, ELISA, dot-ELISA, direct agglutination test) often results in low titers that cannot define disease or a healthy condition.

Based on the results of this study, it appears that the Western blot is able to discriminate early phases of the disease in animals that are negative or have low antibody titers with the techniques mentioned above. The presence of antibodies specific to the 12- and 14-kD fractions in asymptomatic dogs may last for a variable period of time and positivity by dot-ELISA and/or clinical disease has been observed up to six years after detecting the presence of these specific antibodies. This is in agreement with previous observations that when healthy dogs seroconverted, the first bands to appear on Western blots were those of 14 and 16 kD. Moreover, the long period during which such bands may be found in asymptomatic dogs before they reach the cut-off level of the dot-ELISA could explain previous findings that fractions of low molecular weight were recognized by human controls in endemic areas in France and Spain, but not by humans from nonendemic regions.

Dogs that showed a regression of the disease and of antibody titers (group D) had a reduced activity to certain antigen bands: those to the 12- and 14-kD bands disappeared or were reduced in intensity while others to higher molecular weight bands remained. This suggests that in some cases the presence of specific antibodies to antigens of high molecular weight (> 46 kD) could be related to previous contact with the parasite. Nevertheless, the significance of some bands of high molecular weights, in particular those of 60, 65, 70, and 75 kD, which often appear associated, is not clear because they were sporadically recognized by sera of dogs from nonendemic areas. These bands were also recognized by a high proportion of human negative control sera in Catalonia and southern France, which are areas endemic for leishmaniasis. Proteins of 70- and 72-kD in Leishmania antigens have been identified as members of the highly conserved heat-shock protein 70 (hsp70) family, and they are recognized not only by most human visceral leishmaniasis sera but also by sera from patients with other infectious diseases, such as tuberculosis, toxoplasmosis, and hydatidosis. The response in dogs to hsp70 during leishmaniasis is specifically elicited by the parasite protein and is not an autoimmune reaction. Nevertheless, the similarity between hsp70 from different infectious agents could explain the presence of cross-reactive antibodies.

This study corroborates the high sensitivity (95.8%) and specificity (100%) of Western blots for the diagnosis of ca-
nine leishmaniasis when antigen bands with molecular weights of 12, 14, 28, 30, and 46 kD are considered. The main advantage of Western blots over other serologic techniques that use whole *Leishmania* antigen is in its capacity to discriminate early asymptomatic infections. Identification of the 12- and 14-kD antigen fractions of *Leishmania* in dogs can be used to detect early phases of this disease, which can last many years, and possibly to evaluate the resolution of the disease.

Acknowledgments: We acknowledge the facilities provided by veterinarians, local councils, and people from the Priorat region. We also thank Professors A. Uggla (Uppsala, Sweden), C. Bordier (Lausanne, Switzerland), and B. Valladares (La Laguna, Canary Islands) for providing negative controls, and R. Rycroft for correcting the English version of the manuscript.

Financial support: This work was supported by the Secretaria de Estado de Universidades e Investigacion through projects PB86-0546, SAL90-0960-CO2, and PB94-0865.


RECENT REFERENCES


